In silico analysis of white turmeric cholorogenic acid compound as angiotensin-converting Enzyme-2 (ACE2) inhibitor for COVID-19 drug candidate Available to Purchase

COVID-19 is a disease caused by SARS-CoV2 that had spread in 218 countries. The use of bioactive compound- based antivirals needed to be considered for COVID-19 treatment. One of the potential bioactive ingredients in COVID- 19 treatment is chlorogenic acid of white turmeric (Curcuma zedoaria). One of target proteins for chlorogenic acid is Angiotensin Converting Enzyme-2 (ACE2) which is associated with the SARS-CoV2 infection pathway. A strategy that could be used for COVID-19 drugs design was by inhibiting ACE2, a viral receptor, using chlorogenic acid compounds from white turmeric. This study was aimed to predict chlorogenic acid compounds of white turmeric to inhibit ACE2 through reverse docking. Docking was done with Pyrx and visualized with PyMol and Discovery Studio software. Data gained from software and webserver were analyzed descriptively and compared with three control compounds. The results of this study concluded that chlorogenic acid from white turmeric could be recommended as oral COVID-19 drugs candidate.